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OBJECTIVES: Finland has been amodel country for an organised
population-based cervical cancer (CC) screening programme.
Since its implementation in the 1960’s, both CC incidence and
mortality rates have reduced by 80% to annual 150 CC cases and
50–60 CC deaths. Our objective was to predict the clinical impact
of introducing prophylactic vaccination against human papillo-
mavirus (HPV) within a well functioning organised population-
based screening system and to evaluate the cost-effectiveness of
vaccination using a cohort based Markov model. METHODS:
The model is based upon lifetime Markov processes using
Microsoft Excel, modelling the natural history of HPV infection
and CC over the lifetime of a one age-cohort of girls. The model
simulates the effect of adding vaccination to the current screening
programme in terms of number of pre-cancerous lesions, CC cases
and CC deaths avoided. Data is collected from literature review,
expert opinion and statistics in Finland. All country speciﬁc data
were reviewed with national experts. Screening coverage was
assumed to remain constant over time in the model (2.1 million
eligible women and ca. 500,000 annual Pap smears divided into
different screening patterns). RESULTS: With 90% vaccination
coverage, coinciding with the coverage of the Finnish mass vacci-
nation programme, the model predicts a 66% reduction in CC
cases and in CC deaths (from 166 to 56 and from 56 to 19,
respectively). Cost-effectiveness was estimated assuming vaccine
price of €120/dose, including administration. With the assumed
coverage the undiscounted ICERwould be less than €7000/QALY.
CONCLUSION:AlthoughCC cases and deaths are relatively rare
in Finland, it would still be very cost-effective to implement
prophylactic cervical cancer vaccination. Additional beneﬁts
include avoidance of pre-cancerous lesions, the resource use
related to these and their adverse utility effects.
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OBJECTIVES: The efﬁciency of the Finnish cervical cancer (CC)
screening system is renowned. Consequently, the burden of CC in
Finland is amongst the lowest in the world. Our objective was to
validate, in this unusual setting, a cohort based Markov model
developed for estimating the clinical and health economic impact
of adding a prophylactic vaccine against cervical cancer to an
existing screening programme. METHODS: An existing Markov
model describing the natural history of high-risk HPV infections
to CC combined with screening was customized to the Finnish
setting. Basic calibration was performed using published data and
information on the existing screening programme. One third of
total annual pap smears are taken within organized population-
based screening. However, the remaining two thirds of total paps
(private spontaneous screening) are crucial for the outcomes. In
our model, spontaneous screening was extrapolated assuming a
similar age-speciﬁc distribution to organised screening. Themodel
outcomes of a cohort of 30,000 girls aged 11 years were validated
against the age-speciﬁc annual number of total pap smears, CC
incidence and CC mortality reported over the last 15 years in
Finnish statistics.RESULTS:Observed age-speciﬁc CC incidences
and deaths were closely replicated by the model (correlation
coefﬁcients 0.702 and 0.826, respectively). Overall predicted and
observedCC incidence andmortality adjusted forworld standard-
ized population per 100,000 women coincide (CC 4.2 vs. 4.0;
mortality 1.2 vs. 1.2, respectively). The predicted lifetime number
of pre-cancerous lesions for the cohort were 14,462 (CIN1) and
1,646 (CIN2-3). The model predicts that vaccination at 90%
coverage would reduce CC cases andmortality by 66% (166 to 56
cases; 56 to 19 deaths). CONCLUSION: A Markov model can be
used to replicate cancer incidence and mortality in the unique
Finnish setting. This model predicts health beneﬁts and cost-
effectiveness of a vaccine against cervical cancer in Finland.
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OBJECTIVES: The objective of this study is to elicit preferences
for hypothetical risks and beneﬁts of antiretroviral (ART) treat-
ment among treatment-naïve HIV-positive African-Americans
using a stated-choice (SC) survey with probabilistic attribute
levels. SC surveys often include attributes that describe disease
outcomes and treatment features as discrete levels. Rarely do
studies describe attributes in probabilistic terms. Understanding
and conceptualizing numerical probabilities often is cognitively
challenging. Researchers have experimented with various graphi-
cal representations to assist respondents in understanding quan-
titative risks, but there is no general consensus about the most
effective approach. METHODS: In a recent study to estimate the
willingness of treatment-naïve HIV-positive African-Americans to
accept adverse event risks in exchange for improvements in treat-
ment efﬁcacy, four of the ﬁve attributes were described as prob-
abilities. We relied on a format that portrays absolute risks using
a risk grid in which each square of the grid represents one person.
Respondents completed an online survey instrument that included
a series of 10 SC tasks. Each hypothetical treatment alternative
included different probabilities of virologic failure, hypersensitiv-
ity reaction, bone damage, and kidney damage. The ﬁfth attribute
described discrete outcomes of bone or kidney damage (degree to
which the problem could be treated successfully). We included
four questions that tested their understanding of the risk grid
format prior to completing the choice questions. RESULTS: In
total, 153 respondents completed the survey. The mean (SD) age
was 42 (8.6) and there were slightly more males (58%) than
females (42%). Seventy-four percent (89%) of respondents
answered the ﬁrst (fourth) risk quiz question correctly indicating
a high level of comprehension of risk levels.CONCLUSION:Our
risk grid approach, which included both a numerical and graphi-
cal representation of absolute risk levels, is an appropriatemethod
for including probabilistic attribute levels in SC surveys.
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OBJECTIVES: Due to changes in population, health care system
and methodological factors the external validity of economic
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